Eli Lilly and Company (TSX:LLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.70T +45.2% |
| Revenue (ttm) | 122.75B +45.5% |
| Net Income | 39.15B +49.8% |
| EPS | 1.45 +50.7% |
| Shares Out | n/a |
| PE Ratio | 33.30 |
| Forward PE | 29.11 |
| Dividend | 0.25 (0.51%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 98,643 |
| Open | 48.07 |
| Previous Close | 48.67 |
| Day's Range | 47.46 - 48.96 |
| 52-Week Range | 30.67 - 51.69 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
Healthcare Stocks Fall as Market Rout Spreads
Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.
Hims & Hers and Eli Lilly announce agreement to expand acces to Zepbound
Eli Lilly and Company (LLY) and Hims & Hers Health (HIMS) announced an agreement to help expand access to Zepbound, or tirzepatide, and Foundayo, or orforglipron. Through the agreement, eligible…
Eli Lilly, Hims & Hers enter pact to expand access to Zepbound and Foundayo
Eli Lilly (LLY) and Hims & Hers (HIMS) announced an agreement to help expand access to Zepbound and Foundayo. Through the agreement, eligible patients who receive a prescription from a…
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (or...
LifeMD expands access to Eli Lilly self-pay GLP-1 medicines
LifeMD (LFMD) announced an arrangement with Eli Lilly (LLY) that enables LifeMD’s affiliated pharmacy to directly dispense and ship Lilly’s self-pay GLP-1 medicines, including Zepbound and Foundayo, t...
Eli Lilly price target raised to $1,557 from $1,497 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,557 from $1,497 and keeps a Buy rating on the shares. The firm is applying a higher multiple to…
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some ex...
GLP-1 drugs help control prediabetes better than current standard medicine
Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
3 Healthcare Stocks with ‘Strong Buy’ Analyst Ratings and ‘Perfect 10’ Smart Scores
Eli Lilly ($LLY), UnitedHealth ($UNH), and Gilead Sciences ($GILD) are three healthcare stocks with Strong Buy analyst ratings. All three stocks also have a Perfect 10 Smart Score on TipRanks.
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,440 and keeps an Overweight rating on the shares. Commercial trends over Q4…
Eli Lilly price target raised to $1,600 from $1,400 at Freedom Broker
Freedom Broker analyst Ilya Zubkov raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,400 and keeps a Buy rating on the shares. The company’s Q3 report…
Eli Lilly price target raised to $1,605 from $1,300 at Scotiabank
Scotiabank raised the firm’s price target on Eli Lilly (LLY) to $1,605 from $1,300 and keeps an Outperform rating on the shares. The firm believes Eli Lilly will maintain its…
Eli Lilly price target raised to $1,596 from $1,430 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,596 from $1,430 and keeps an Overweight rating on the shares.
Eli Lilly price target raised to $1,600 from $1,500 at RBC Capital
RBC Capital raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,500 and keeps an Outperform rating on the shares. The company delivered another impressive quarter on…
Eli Lilly price target raised to $1,500 from $1,330 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,330 and keeps an Overweight rating on the shares. The firm says Q4…
Eli Lilly price target raised to $1,612 from $1,376 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,612 from $1,376 and keeps a Buy rating on the shares. The company reported strong Q3 earnings growth, and…
Eli Lilly price target raised to $1,650 from $1,600 at Citi
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,650 from $1,600 and keeps a Buy rating on the shares post the Q3 report. The firm says Lilly…
Eli Lilly price target raised to $1,573 from $1,413 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,573 from $1,413 and keeps a Buy rating on the shares. Eli Lilly rallied 6.6% after its third…
Eli Lilly price target raised to $1,550 from $1,300 at Argus
Argus analyst Jasper Hellweg raised the firm’s price target on Eli Lilly (LLY) to $1,550 from $1,300 and keeps a Buy rating on the shares after its Q3 earnings beat.
Eli Lilly price target raised to $1,650 from $1,500 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly (LLY) to $1,650 from $1,500 and keeps an Overweight rating on the shares post the Q3 report. The…
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion
Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.